SCYX Q4 2021 Earnings — SCYNEXIS, Inc. Revenue & Financial Results | Market Cap Arena

SCYXSCYNEXIS, Inc.

$38M

Q4 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$597,000

Gross Profit

$430,00072.0% margin

Operating Income

-$22M-3734.8% margin

Net Income

-$29M-4898.3% margin

EPS (Diluted)

$-1.05

QoQ Revenue Growth

+15.7%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$560,000

Balance Sheet

Total Assets

$120M

Total Liabilities

$79M

Stockholders' Equity

$41M

Cash & Equivalents

$104M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$597,000	$0	—
Gross Profit	$430,000	$0	—
Operating Income	-$22M	-$15M	-45.4%
Net Income	-$29M	-$43M	+31.5%

Revenue Segments

Product

$597,000100%